AstraZeneca's Baxdrostat Receives FDA Priority Review for Difficult-to-Control Hypertension

AstraZeneca announced that its New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA). The application seeks approval for baxdrostat as a treatment for adult patients experiencing hard-to-control hypertension, specifically when added to existing antihypertensive medications that have not provided sufficient blood pressure lowering.

The FDA's acceptance for Priority Review is a significant step, indicating a focus on potentially offering a new therapeutic option for a challenging medical condition. The Prescription Drug User Fee Act (PDUFA) date is anticipated in the second quarter of 2026. If approved, baxdrostat could become the first aldosterone synthase inhibitor authorized for marketing, targeting a key hormone implicated in elevated blood pressure.

Hypertension affects 1.4 billion people globally, and a substantial portion of patients, particularly in the U.S., struggle to manage their blood pressure effectively even with multiple treatments. Aldosterone is recognized as a critical driver of difficult-to-control hypertension, contributing to increased cardiovascular and renal risks. The condition remains a major public health challenge.

The submission is supported by data from the BaxHTN Phase III trial. This trial demonstrated that baxdrostat, in addition to standard care, achieved statistically significant and clinically meaningful reductions in systolic blood pressure for patients with resistant or uncontrolled hypertension. The drug was generally well tolerated, with a safety profile consistent with its mechanism of action and no unanticipated safety findings.